RAD Technology Medical Systems to Provide VRCC Veterinary Specialty and Emergency Hospital with Standalone Radiotherapy Center

RAD Technology Medical Systems (RAD) is pleased to announce that they will be providing Veterinary Referral Center of Colorado, also know as, VRCC Veterinary Specialty and Emergency Hospital (VRCC) in Sheridan, CO with a veterinary radiotherapy center. This facility will allow VRCC to provide improved radiation therapy treatment to animals with cancer.

RAD’s patented technology and offsite modular construction methods provide their customers with a flexible, high-quality facility solution that is completed ahead of conventional construction.

RAD’s modular radiotherapy center was the perfect solution for the growing VRCC. They were looking for a quick solution that would allow them to upgrade their services in the region. They selected a pre-existing RAD facility that will be updated and expanded to meet all of their specific program needs.

Unlike with conventionally built radiotherapy centers, RAD’s facility and equipment will be able to make Beam within 5-7 days of its arrival on site, and will be ready to treat patients within 30 days of arrival.

This facility originally served as a Temporary Radiotherapy Vault, or RAD Temp, and was previously used by cancer centers from coast to coast, in five states and the District of Columbia, to treat patients while those cancer centers upgraded their radiotherapy equipment.

“We are excited to be entering the Veterinary Market,” said Kenneth Wright, RAD’s Vice President of Sales and Business Development. “The veterinary oncology market is growing and our modular approach is the perfect solution for veterinary offices looking to expand or add radiation treatment to their location.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.